These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 39043809)

  • 1. Effects of genetically proxied statins on diabetic nephropathy and retinopathy: a Mendelian randomization study.
    Zhao R; Wang W; Zhang W; Lu J; Liu Y; Guo J; Yang L; Zhang Z; He C; Gu X; Wang B
    Sci Rep; 2024 Jul; 14(1):16885. PubMed ID: 39043809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study.
    Gormley M; Yarmolinsky J; Dudding T; Burrows K; Martin RM; Thomas S; Tyrrell J; Brennan P; Pring M; Boccia S; Olshan AF; Diergaarde B; Hung RJ; Liu G; Legge D; Tajara EH; Severino P; Lacko M; Ness AR; Davey Smith G; Vincent EE; Richmond RC
    PLoS Genet; 2021 Apr; 17(4):e1009525. PubMed ID: 33886544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between lipid-lowering agents with intervertebral disc degeneration, sciatica and low back pain: a drug-targeted mendelian randomized study and cross-sectional observation.
    Liu C; Chu X; Biao Y; Jin Q; Zhang Y; Gao Y; Feng S; Ma J; Zhang Y
    Lipids Health Dis; 2024 Oct; 23(1):327. PubMed ID: 39358768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer.
    Yarmolinsky J; Bull CJ; Vincent EE; Robinson J; Walther A; Smith GD; Lewis SJ; Relton CL; Martin RM
    JAMA; 2020 Feb; 323(7):646-655. PubMed ID: 32068819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic association of lipid-lowering drugs with aortic aneurysms: a Mendelian randomization study.
    Gao X; Luo W; Qu L; Yang M; Chen S; Lei L; Yan S; Liang H; Zhang X; Xiao M; Liao Y; Lee AP; Zhou Z; Chen J; Zhang Q; Wang Y; Xiu J
    Eur J Prev Cardiol; 2024 Jul; 31(9):1132-1140. PubMed ID: 38302118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study.
    Fang S; Yarmolinsky J; Gill D; Bull CJ; Perks CM; ; Davey Smith G; Gaunt TR; Richardson TG
    PLoS Med; 2023 Jan; 20(1):e1003988. PubMed ID: 36595504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer.
    Sun L; Ding H; Jia Y; Shi M; Guo D; Yang P; Wang Y; Liu F; Zhang Y; Zhu Z
    Breast Cancer Res; 2022 Feb; 24(1):12. PubMed ID: 35151363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of genetically proxied lipid-lowering drugs on acute myocardial infarction: a drug-target mendelian randomization study.
    Xiao W; Li Y; Zhuang Z; Song Z; Wang W; Huang N; Dong X; Jia J; Liu Z; Zhao Y; Qi L; Huang T
    Lipids Health Dis; 2024 Jun; 23(1):163. PubMed ID: 38831433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the Impact of PCSK9 and HMGCR Inhibition on Liver Function: Drug-Target Mendelian Randomization Analyses in Four Ancestries.
    Rosoff DB; Bell AS; Wagner J; Mavromatis LA; Hamandi A; Park L; Jung J; Lohoff FW
    Cell Mol Gastroenterol Hepatol; 2024; 17(1):29-40. PubMed ID: 37703945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations between Genetically Proxied Inhibition of Lipid-Lowering Drug Targets and Serum Micronutrients among Individuals of European Descent: A Mendelian Randomization Study.
    He JY; Zhang X; Wang K; Lv WQ
    J Nutr; 2022 May; 152(5):1283-1290. PubMed ID: 35349717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statins as a risk factor for diabetic retinopathy: a Mendelian randomization and cross-sectional observational study.
    Chen C; Zhang H; Lan Y; Yan W; Liu S; Chen Y; Xie T; Ning J; Yan X; Shang L; Han J
    J Transl Med; 2024 Mar; 22(1):298. PubMed ID: 38520016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug Target Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Atrial Fibrillation.
    Li F; Mei Y; Wu Q; Wu X
    Cardiology; 2024; 149(5):495-501. PubMed ID: 38531334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of lipid-lowering drugs with risk of sarcopenia: a drug target mendelian randomization study and meta-analysis.
    Li J; Zang C; Lv H; Xiao Z; Li P; Xiao B; Zhou L
    Hum Genomics; 2024 Jul; 18(1):76. PubMed ID: 38961447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Causal relationship between PCSK9 inhibitor and primary glomerular disease: a drug target Mendelian randomization study.
    Duan H; Shi Y; Zhang Q; Shi X; Zhang Y; Liu J; Zhang Y
    Front Endocrinol (Lausanne); 2024; 15():1335489. PubMed ID: 38510702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetically proxied therapeutic inhibition of lipid-lowering drug targets and risk of rheumatoid arthritis disease: a Mendelian randomization study.
    Qiao L; Lv S; Meng K; Yang J
    Clin Rheumatol; 2024 Mar; 43(3):939-947. PubMed ID: 38198113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid traits and type 2 diabetes risk in African ancestry individuals: A Mendelian Randomization study.
    Soremekun O; Karhunen V; He Y; Rajasundaram S; Liu B; Gkatzionis A; Soremekun C; Udosen B; Musa H; Silva S; Kintu C; Mayanja R; Nakabuye M; Machipisa T; Mason A; Vujkovic M; Zuber V; Soliman M; Mugisha J; Nash O; Kaleebu P; Nyirenda M; Chikowore T; Nitsch D; Burgess S; Gill D; Fatumo S
    EBioMedicine; 2022 Apr; 78():103953. PubMed ID: 35325778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mendelian randomization study of lipid metabolism characteristics and migraine risk.
    Hong P; Han L; Wan Y
    Eur J Pain; 2024 Jul; 28(6):978-986. PubMed ID: 38183343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic insights into the association of statin and newer nonstatin drug target genes with human longevity: a Mendelian randomization analysis.
    Chen H; Zhou X; Hu J; Li S; Wang Z; Zhu T; Cheng H; Zhang G
    Lipids Health Dis; 2023 Dec; 22(1):220. PubMed ID: 38082436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the causal effect between lipid-modifying drugs and idiopathic pulmonary fibrosis: a drug-target Mendelian randomization study.
    Cai G; Liu J; Cai M; Shao L
    Lipids Health Dis; 2024 Aug; 23(1):237. PubMed ID: 39090671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Causal relationship between lipid-lowering drugs and ovarian cancer, cervical cancer: a drug target mendelian randomization study.
    Li J; Yang Z; Wang T; Li M; Wu X; Fu X; Yang C; Li Y; Wang X; Lan Z; Li M; Chen S
    BMC Cancer; 2024 May; 24(1):667. PubMed ID: 38822303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.